{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T02:05:36Z","timestamp":1790301936592,"version":"4.1.0"},"reference-count":27,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,4,28]],"date-time":"2025-04-28T00:00:00Z","timestamp":1745798400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinicaltherapeutics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Therapeutics"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1016\/j.clinthera.2025.04.017","type":"journal-article","created":{"date-parts":[[2025,5,22]],"date-time":"2025-05-22T15:51:54Z","timestamp":1747929114000},"page":"624-630","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["Comparative Analysis of Adverse Events Linked to PEG-rhG-CSF and rhG-CSF in Real-World Settings: Disproportionate Examination of the US Food and Drug Administration (FDA) Adverse Event Reporting System (FAERS) Database"],"prefix":"10.1016","volume":"47","author":[{"given":"Ying","family":"Qu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li\u2019an","family":"Zuo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuting","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wanyi","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rong","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinthera.2025.04.017_bib0001","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1016\/S0140-6736(22)01390-3","article-title":"Early drug development in solid tumours: analysis of National Cancer Institute-sponsored phase 1 trials","volume":"400","author":"Chihara","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.clinthera.2025.04.017_bib0002","first-page":"3131","article-title":"The impact of primary prophylaxis with granulocyte colony-stimulating factors on febrile neutropenia during chemotherapy: a systematic review and meta-analysis of randomized controlled trials","volume":"23","author":"Wang","year":"2015","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.clinthera.2025.04.017_bib0003","doi-asserted-by":"crossref","first-page":"3199","DOI":"10.1200\/JCO.2015.62.3488","article-title":"Recommendations for the use of WBC growth factors: American Society of Clinical Oncology Clinical Practice Guideline Update","volume":"33","author":"Smith","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clinthera.2025.04.017_bib0004","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1200\/jop.2006.2.4.196","article-title":"2006 Update of ASCO practice guideline recommendations for the use of white blood cell growth factors: guideline summary","volume":"2","author":"Smith","year":"2006","journal-title":"J Oncol Pract"},{"key":"10.1016\/j.clinthera.2025.04.017_bib0005","doi-asserted-by":"crossref","first-page":"491","DOI":"10.2165\/00044011-200929080-00001","article-title":"Implications of the European Organisation for Research And Treatment Of Cancer (EORTC) guidelines on the use of granulocyte colony-stimulating factor (G-CSF) for lymphoma care","volume":"29","author":"Pettengell","year":"2009","journal-title":"Clin Drug Investig"},{"key":"10.1016\/j.clinthera.2025.04.017_bib0006","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1188\/09.CJON.324-328","article-title":"Filgrastim and pegfilgrastim use in patients with neutropenia","volume":"13","author":"Quirion","year":"2009","journal-title":"Clin J Oncol Nurs"},{"issue":"2","key":"10.1016\/j.clinthera.2025.04.017_bib0007","doi-asserted-by":"crossref","DOI":"10.1136\/bcr-2021-242316","article-title":"Acute respiratory distress syndrome precipitated by granulocyte colony-stimulating factor in undiagnosed Pneumocystis jirovecii pneumonia","volume":"15","author":"Doig","year":"2022","journal-title":"BMJ Case Rep"},{"key":"10.1016\/j.clinthera.2025.04.017_bib0008","doi-asserted-by":"crossref","first-page":"E333","DOI":"10.1002\/ajh.25220","article-title":"Granulocyte colony-stimulating factors and aortitis: A rare adverse event","volume":"93","author":"Lardieri","year":"2018","journal-title":"Am J Hematol"},{"key":"10.1016\/j.clinthera.2025.04.017_bib0009","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1186\/s40792-021-01282-9","article-title":"Drug-induced aortitis of the subclavian artery caused by pegfilgrastim: a case report","volume":"7","author":"Jimbo","year":"2021","journal-title":"Surg Case Rep"},{"key":"10.1016\/j.clinthera.2025.04.017_bib0010","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1148\/radiol.220357","article-title":"Single-center analysis of pegfilgrastim-induced aortitis using a drug prescription database and CT findings","volume":"305","author":"Takamatsu","year":"2022","journal-title":"Radiology"},{"key":"10.1016\/j.clinthera.2025.04.017_bib0011","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1016\/j.ekir.2022.02.014","article-title":"Anticancer drug-induced capillary leak syndrome","volume":"7","author":"Hassan","year":"2022","journal-title":"Kidney Int Rep"},{"key":"10.1016\/j.clinthera.2025.04.017_bib0012","article-title":"Spontaneous splenic rupture as a rare complication of G-CSF injection","author":"Soraya","year":"2018","journal-title":"BMJ Case Rep"},{"key":"10.1016\/j.clinthera.2025.04.017_bib0013","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1002\/pds.3805","article-title":"Standardisation of the FAERS database: a systematic approach to manually recoding drug name variants","volume":"24","author":"Wong","year":"2015","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.1016\/j.clinthera.2025.04.017_bib0014","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1080\/03007995.2019.1703665","article-title":"Prophylaxis of febrile neutropenia with colony-stimulating factors: the first 25 years","volume":"36","author":"Edelsberg","year":"2020","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.clinthera.2025.04.017_bib0015","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1007\/s40259-020-00466-3","article-title":"Safety of marketed cancer supportive care biosimilars in the US: A disproportionality analysis using the Food and Drug Administration Adverse Event Reporting System (FAERS) Database","volume":"35","author":"Tanni","year":"2021","journal-title":"BioDrugs"},{"key":"10.1016\/j.clinthera.2025.04.017_bib0016","first-page":"2703","article-title":"Pegfilgrastim versus Filgrastim for primary prophylaxis of Febrile neutropenia in patients with non-Hodgkin\u2019s lymphoma: A cost-effectiveness study","volume":"18","author":"Ravangard","year":"2017","journal-title":"Asian Pac J Cancer Prev"},{"key":"10.1016\/j.clinthera.2025.04.017_bib0017","first-page":"5085","article-title":"Is PEGylated G-CSF superior to G-CSF in patients with breast cancer receiving chemotherapy? A systematic review and meta-analysis","volume":"28","author":"Li","year":"2020","journal-title":"Support Care Cancer"},{"issue":"2","key":"10.1016\/j.clinthera.2025.04.017_bib0018","first-page":"340","article-title":"Comparative study of adverse drug reactions associated with Filgrastim and Pegfilgrastim using the EudraVigilance Database","volume":"11","author":"Rastogi","year":"2022","journal-title":"Biology (Basel)"},{"key":"10.1016\/j.clinthera.2025.04.017_bib0019","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.ejca.2017.10.034","article-title":"Comparing granulocyte colony-stimulating factor filgrastim and pegfilgrastim to its biosimilars in terms of efficacy and safety: A meta-analysis of randomised clinical trials in breast cancer patients","volume":"89","author":"Botteri","year":"2018","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.clinthera.2025.04.017_bib0020","doi-asserted-by":"crossref","first-page":"2283","DOI":"10.1185\/030079907X219599","article-title":"Comparison of pegfilgrastim with filgrastim on febrile neutropenia, grade IV neutropenia and bone pain: a meta-analysis of randomized controlled trials","volume":"23","author":"Pinto","year":"2007","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.clinthera.2025.04.017_bib0021","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.critrevonc.2013.08.006","article-title":"The five \u201cws\u201d for bone pain due to the administration of granulocyte-colony stimulating factors (G-CSFs)","volume":"89","author":"Lambertini","year":"2014","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/j.clinthera.2025.04.017_bib0022","doi-asserted-by":"crossref","first-page":"1974","DOI":"10.1200\/JCO.2011.37.8364","article-title":"Prevention of pegfilgrastim-induced bone pain: a phase III double-blind placebo-controlled randomized clinical trial of the university of rochester cancer center clinical community oncology program research base","volume":"30","author":"Kirshner","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clinthera.2025.04.017_bib0023","first-page":"8151","article-title":"Evaluating the safety and effectiveness of PegaGen((R)) (pegfilgrastim) for the prevention of chemotherapy-induced febrile neutropenia: a post-marketing surveillance study","volume":"30","author":"Jenabian","year":"2022","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.clinthera.2025.04.017_bib0024","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1002\/pds.4218","article-title":"Comparative study of the number of report and time-to-onset of the reported adverse event between the biosimilars and the originator of filgrastim","volume":"26","author":"Kobayashi","year":"2017","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.1016\/j.clinthera.2025.04.017_bib0025","doi-asserted-by":"crossref","first-page":"2195","DOI":"10.1007\/s15010-024-02248-3","article-title":"Safety evaluation of ceftazidime\/avibactam based on FAERS database","volume":"52","author":"Zhang","year":"2024","journal-title":"Infection"},{"key":"10.1016\/j.clinthera.2025.04.017_bib0026","doi-asserted-by":"crossref","first-page":"1277734","DOI":"10.3389\/fimmu.2023.1277734","article-title":"Dupilumab and the potential risk of eosinophilic pneumonia: case report, literature review, and FAERS database analysis","volume":"14","author":"Zhou","year":"2023","journal-title":"Front Immunol"},{"key":"10.1016\/j.clinthera.2025.04.017_bib0027","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1080\/14740338.2023.2130888","article-title":"Evaluation of adverse events of bamlanivimab, bamlanivimab\/etesevimab used for COVID-19 based on FAERS database","volume":"22","author":"Zhao","year":"2023","journal-title":"Expert Opin Drug Saf"}],"container-title":["Clinical Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291825001596?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291825001596?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T13:07:40Z","timestamp":1753880860000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0149291825001596"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8]]},"references-count":27,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2025,8]]}},"alternative-id":["S0149291825001596"],"URL":"https:\/\/doi.org\/10.1016\/j.clinthera.2025.04.017","relation":{},"ISSN":["0149-2918"],"issn-type":[{"value":"0149-2918","type":"print"}],"subject":[],"published":{"date-parts":[[2025,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Comparative Analysis of Adverse Events Linked to PEG-rhG-CSF and rhG-CSF in Real-World Settings: Disproportionate Examination of the US Food and Drug Administration (FDA) Adverse Event Reporting System (FAERS) Database","name":"articletitle","label":"Article Title"},{"value":"Clinical Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clinthera.2025.04.017","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}